#Italy #Florence #Sinocare #Menarini Diagnostics #glucose monitoring

A. Menarini Diagnostics and Sinocare Join Forces for Diabetes Care

In a significant move for diabetes management in Europe, A. Menarini Diagnostics has announced an exclusive distribution agreement with Sinocare, a leading innovator in glucose monitoring technology. This partnership enables Menarini to promote, distribute, and market Sinocare's third-generation Continuous Glucose Monitoring (CGM) system in over 20 European jurisdictions.

Enhancing Diabetes Management Technology

The collaboration is set to revolutionize diabetic care with a sophisticated CGM that offers continuous and accurate blood glucose monitoring. This technology marks a pivotal advancement in how diabetes is managed, making it easier for patients to track their glucose levels and make informed health decisions.

Dr. Jiangfeng Fei, the head of Sinocare’s CGM business unit, emphasized the importance of this partnership in expanding access to innovative diabetes management solutions. He stated, "Partnering with A. Menarini Diagnostics is a significant milestone in our mission to make our third-generation CGM systems widely available to those living with diabetes. We are excited to collaborate with such a notable leader in healthcare to bring this cutting-edge technology to a broader audience."

Commitment to Innovation

Fabio Piazzalunga, the global CEO of A. Menarini Diagnostics, echoed this sentiment, highlighting the long-term commitment to addressing the growing need for advanced diabetes care solutions. He remarked, "Acquiring exclusive distribution rights for Sinocare's innovative CGM technology in numerous countries aligns with our dedication to delivering groundbreaking healthcare solutions. We are confident that this long-term partnership will meet the increasing demand for advanced diabetes management."

Strategic Market Expansion

With their extensive networks and resources, A. Menarini Diagnostics aims to ensure that Sinocare’s third-generation CGM systems reach patients who will benefit most from these advanced capabilities. The alliance not only enhances the availability of advanced glucose monitoring solutions but also reaffirms Menarini's commitment to innovative healthcare technologies that improve patient outcomes.

Having been a forefront player in healthcare for over 45 years, A. Menarini Diagnostics has built a legacy of delivering reliable and effective diagnostic tools. It operates in 140 countries and has a workforce of more than 17,000 employees, generating a revenue of €4.375 billion in 2023.

Sinocare, on the other hand, established itself as the largest glucose monitoring device manufacturer in Asia, having been founded in 2002. It was the first Chinese company to be publicly listed as a blood glucose meter manufacturer. With a growing international presence across Asia, Europe, and North America, Sinocare has expanded its market reach through strategic partnerships and acquisitions, such as those with PTS Diagnostics Inc. and Nipro Diagnostic Inc.

The Future of Diabetes Care

This partnership represents more than just a business agreement; it reflects a collective commitment to advancing diabetes care and ensuring that patients have access to state-of-the-art monitoring devices that enhance their quality of life. As the healthcare landscape evolves, partnerships like that of A. Menarini and Sinocare will play a critical role in shaping the future of diabetes management.

In conclusion, the exclusive distribution agreement between A. Menarini Diagnostics and Sinocare paves the way for a new era in diabetes care. By harnessing each other's strengths, they are poised to deliver innovative solutions that not only meet patient needs but also contribute to improved health outcomes across Europe.